FDA Issues EUA for the Use of Hydroxychloroquine and Chloroquine
On Sunday March 29, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to permit the emergency use of hydroxychloroquine sulfate and chloroquine phosphate. The drugs, which have been used to treat Malaria for decades, have been observed to perform positively in COVID-19 patients.
“The EUA requires that fact sheets (which) provide important information about using chloroquine phosphate and hydroxychloroquine sulfate in treating COVID-19 be made available to health care providers and patients, including the known risks and drug interactions.”(a)
Follow the links below to access the documents published by the FDA. Also included is the link to the related Declaration from FDA’s Department of Health and Human Services.
Chloroquine Fact Sheets
Hydroxychloroquine Fact Sheets
- Department of Health and Human Services – https://www.hhs.gov/about/news/2020/03/29/hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html. Accessed Monday, March 30, 2020.
The U.S Food and Drug Administration’s Photostream. November 24, 2010. “FDA Sign & Bldg 21 at Entrance.” Digital Image. Flickr. Yahoo! Inc. Web. Accessed: 30 March 2020.
Who We Are
Eagle consultants and scientists are helping compounding facilities implement successful quality systems. Our team has over 200 years of combined experience in the FDA-regulated pharmaceutical industry and can provide guidance in establishing the systems and processes that will help facilities producing compounded medications meet and exceed regulatory expectations. Follow the link below to learn more about our consulting services.
- Antimicrobial Effectiveness | USP 795 & 797 Revisions - July 18, 2023
- 2023 PDA/FDA Joint Regulatory Conference, 09/18 – 09/20 - July 11, 2023
- APC: Compounders on Capitol Hill, 09/19 – 09/20 - July 11, 2023